Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2016. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
Material Changes
The filing details the Company's issued share capital as of January 31, 2016:
- Total Issued Ordinary Shares: 5,361,605,810 (25p each).
- Treasury Shares: 491,515,950.
- Total Voting Rights: 4,870,089,860.
No comparative data for prior periods is included in this specific filing.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to statutory disclosure of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (4,870,089,860) for compliance with Financial Conduct Authority disclosure thresholds.
- Confirm the number of shares held in Treasury (491,515,950) to calculate the correct denominator for ownership percentage calculations.
- Review the Company's Form 20-F for comprehensive financial performance data, as this 6-K does not contain financial results.